IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES

被引：0
|
作者：
Choueri, Toni K. [1 ]
Fishman, Mayer N. [2 ]
Escudier, Bernard [3 ]
McDermott, David F. [4 ]
Kluger, Harriet [5 ]
Stadler, Walter M. [6 ]
Perez-Gracia, Jose L. [7 ]
McNeel, Douglas [8 ]
Curti, Brendan [9 ]
Harrison, Michael R. [10 ]
Plimack, Elizabeth R. [11 ]
Appleman, Leonard [12 ]
Fong, Lawrence [13 ]
Drake, Charles G. [14 ]
Young, Tina C. [15 ]
Chasalow, Scott D. [15 ]
Ross-Macdonald, Petra [15 ]
Simon, Jason S. [15 ]
Walker, Dana [15 ]
Sznol, Mario [5 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Yale Canc Ctr, New Haven, CT USA
[6] Univ Chicago, Med, Chicago, IL 60637 USA
[7] Univ Navarra Clin, Pamplona, Spain
[8] Univ Wisconsin, Dept Med, Madison, WI USA
[9] Providence Portland Med Ctr, Providence Canc Ctr, Portland, OR USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[13] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[14] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
Asia-Pacific Journal of Clinical Oncology | 2015年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [41] A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon Carter
    Desai, Kunal
    Kao, Chester
    Kinsey, Emily Noelle
    Healy, Patrick
    Kephart, Julie
    Harrison, Michael Roger
    Ramalingam, Sundhar
    Armstrong, Andrew J.
    George, Daniel J.
    Martin, Allison
    Allman, Kimberly D.
    Wood, Laura S.
    Wei, Wei
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Gupta, Shilpa
    Rini, Brian I.
    Ornstein, Moshe Chaim
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Metastatic Renal Cell Carcinoma (mRCC) Clinical Evidence and Quality of Supply in Germany
    Krause, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (12) : 795 - 795
  • [43] GENOMIC BIOMARKERS OF RESPONSE TO NIVOLUMAB/IPILIMUMAB AND NIVOLUMAB MONOTHERAPY IN 108 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    DiNatale, Renzo
    Lee, Chung-Han
    Chowell, Diego
    Makarov, Vladimir
    Redzematovic, Almedina
    Murray, Samuel
    Carlo, Maria
    Voss, Martin
    Coleman, Jonathan
    Russo, Paul
    Motzer, Robert
    Chan, Timothy
    Hakimi, Ari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E346 - E346
  • [44] Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
    Lefort, F.
    Dalban, C.
    Gross-Goupil, M.
    Laguerre, B.
    Barthelemy, P.
    Sarradin, V.
    Chanez, B.
    Negrier, S.
    Geoffrois, L.
    Gillon, P.
    De Vries, M.
    Ladoire, S.
    Bolognini, C.
    Laramas, M.
    Priou, F.
    Oudard, S.
    Chabot, S.
    Tantot, F.
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 391 - 391
  • [45] Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
    Singla, Nirmish
    Nirschl, Thomas
    Obradovic, Aleksandar
    Shenderov, Eugene
    Lombardo, Kara A.
    Liu, Xiaopu
    Pons, Alice
    Zarif, Jelani
    Rowe, Steven P.
    Trock, Bruce J.
    Hammers, Hans J.
    Bivalacqua, Trinity
    Pierorazio, Phillip
    Deutsch, Julie S.
    Lotan, Tamara L.
    Taube, Janis M.
    Ged, Yasser
    Gorin, Michael A.
    Allaf, Mohamad E.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [46] Burden of cancer in metastatic renal cell carcinoma (mRCC).
    Battle, Dena
    Griffith, Meghan
    Msaouel, Pavlos
    Psutka, Sarah P.
    Vaishampayan, Ulka N.
    Zhang, Tian
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [47] Impact of site-specific metastases and clinical complications on outcomes of patients with metastatic renal cell carcinoma (mRCC).
    Wang, Jianbo
    Zhang, Ning
    Giordano, Sharon H.
    Tannir, Nizar M.
    Gao, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16527 - E16527
  • [48] The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC).
    Rhinehart, Dena
    Feinaj, Ardit
    Zahurak, Marianna
    Linville, Laura Meili
    Singla, Nirmish
    Lansey, Dina
    Markowski, Mark Christopher
    Carducci, Michael A.
    Elias, Roy
    Ged, Yasser
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [49] Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.
    Mittal, Kriti
    Derosa, Lisa
    Albiges, Laurence
    Wood, Laura S.
    Elson, Paul
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Dreicer, Robert
    Escudier, Bernard J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)
    Verzoni, E.
    Carteni, G.
    Cortesi, E.
    Roila, F.
    Vitale, M. G.
    Buti, S.
    Pignata, S.
    Cognetti, F.
    Giustini, L.
    Damiani, A.
    Turci, D.
    Sternberg, C. N.
    Porta, C.
    Carrozza, F.
    Tortora, G.
    Tassinari, D.
    Passalacqua, R.
    Pazzola, A.
    Surico, G.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 314 - 314
12345